Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $5.584B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.11pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | $20.89 | Day High | $21.99 | Day Low | $20.89 | |||
| Daily Volume | 9371 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | $21.20 | 1000 | 0 | $21.99 | 359 | |
Directors & Senior Management
| Mr. Alan F. Estevez | Independent Director |
| Mr. Andrew Frazer | Independent Director |
| Mr. Antonio Correa de Sa | Chief Executive Officer of BTW |
| Mr. Daniel G. D'Amato | Non-Independent Director |
| Mr. David Hartley Hanick | Director |
| Mr. Guillaume Wiesenbach de Luxembourg | Chief Development Officer |
| Lieutenant General Gustave F. Perna | Independent Director |
| Mr. John Yi | President - Almonty Korea Tungsten |
| Mr. Jorge Mariano Beristain | Chief Financial Officer |
| Mr. M. Lewis Black | Chairman, President & CEO |
| Ms. Marion McGrath | Corporate Secretary |
| Mr. Mark A. Trachuk | Independent Lead Director |
| Brig.Gen. Steven L. Allen | Chief Operating Officer |
| Mr. Ujin Choi | Project Managing Director of the Sangdong Mine |
Data source: ADVFN
